Lu Si

9.3k citations

309 papers · 4.8k · 2 hit papers · h-index 34

Impact in

Oncology top 1%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Immunology top 5%
- Immunotherapy and Immune Responses

Papers in

Oncology 147
- Cutaneous Melanoma Detection and Management 82
- Cancer Immunotherapy and Biomarkers 57
- CAR-T cell therapy research 50
Molecular Biology 96
- Melanoma and MAPK Pathways 61

Co-authors: Jun Guo (134 shared papers)Xinan Sheng (145 shared papers)Chuanliang Cui (140 shared papers)Zhihong Chi (131 shared papers)Lili Mao (84 shared papers)Yan Kong (77 shared papers)Bin Lian (112 shared papers)Jie Dai (74 shared papers)
Journals: Journal of Clinical Oncology (90 papers)Annals of Oncology (14 papers)European Journal of Cancer (11 papers)BMC Cancer (7 papers)Clinical Cancer Research (7 papers)
Partner nations: China Ethiopia United States

In The Last Decade

Lu Si

285 papers receiving 4.8k citations

Lu Si's Hit Papers

align trajectories log scale

Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells 2025 · 24 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Nature Communications
2020 Clinical Cancer Research

Peers

Countries citing papers authored by Lu Si

Since Specialization

Citations

This map shows the geographic impact of Lu Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Si more than expected).

Fields of papers citing papers by Lu Si

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Si. The network helps show where Lu Si may publish in the future.

Co-authors

The 25 scholars most cited alongside Lu Si, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lu Si Line = papers co-authored together Lu Si links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 309 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases BMC Cancer ·Zhihong Chi, Siming Li, Xinan Sheng, Lu Si, Chuanliang Cui, Mei Han, Jun Guo	2011	276
2	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Clinical Cancer Research ·Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Chang-Lu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, Jun Guo Hit paper breakdown →	2020	212
3	Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort European Journal of Cancer ·Lu Si, Yan Kong, Xiaowei Xu, Keith T. Flaherty, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Lili Mao, Jun Guo	2011	193
4	Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma Clinical Cancer Research ·Yan Kong, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lü, Jun Guo	2011	190
5	Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients Journal of Hematology & Oncology ·Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo	2018	150
6	Depth Enhancement via Low-Rank Matrix Completion Lu Si, Xiaofeng Ren, Feng Liu	2014	134
7	Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Clinical Cancer Research ·Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, Jun Guo	2013	130
8	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions Frontiers in Immunology ·Lili Mao, Zhonghui Qi, Li Zhang, Jun Guo, Lu Si	2021	103
9	The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients Annals of Oncology ·Bin Lian, C-L. Cui, Li Zhou, Xiao‐Tong Song, X.S. Zhang, Di Wu, Lu Si, Z. Chi, X. N. SHENG, Lanfang MAO, X. Wang, B.X. Tang, Xuena Yan, Yan Kong, Jie Dai, Sm Li, Xue Bai, Nan Zheng, Charles M. Balch, Jun Guo	2016	103
10	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151) Translational Oncology ·Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Yu Zhou, Jun Ge, Jianfeng Li, Haiyan Wu, Jun Guo	2019	99
11	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma Molecular Therapy ·Chuanliang Cui, Lili Mao, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Siming Li, Bin Lian, Kangsheng Gu, Min Tao, Xin Song, Tongyu Lin, Xiubao Ren, Shukui Qin, Jun Guo	2013	86
12	MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases Clinical Cancer Research ·Xue Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian, Xieqiao Yan, Li Zhou, Jie Dai, Jun Guo, Lu Si	2017	76
13	Modeling and analysis of rumor propagation in social networks Information Sciences ·Zhenhua Yu, Lu Si, Dan Wang, Zhiwu Li	2021	76
14	The Repressive Effect of miR-148a on TGF beta-SMADs Signal Pathway Is Involved in the Glabridin-Induced Inhibition of the Cancer Stem Cells-Like Properties in Hepatocellular Carcinoma Cells PLoS ONE ·Fei Jiang, Juan Mu, Xingxing Wang, Xianqing Ye, Lu Si, Shilong Ning, Zhong Li, Yuan Li	2014	70
15	Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma npj Genomic Medicine ·Chuanliang Cui, Canqiang Xu, Wenxian Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Jinyu Yu, Shun Wang, Rongshan Yu, Jun Guo, Yan Kong	2021	66
16	CircUBAP2-mediated competing endogenous RNA network modulates tumorigenesis in pancreatic adenocarcinoma Aging ·Rongjie Zhao, Junjie Ni, Lu Si, Sujing Jiang, Liangkun You, Hao Liu, Jiawei Shou, (unknown), Wei Zhang, Shengpeng Shao, Xinmei Yang, Hongming Pan, Weidong Han	2019	64
17	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors Clinical Cancer Research ·Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo	2015	60
18	Deriving Polarimetry Feature Parameters to Characterize Microstructural Features in Histological Sections of Breast Tissues IEEE Transactions on Biomedical Engineering ·Yang Dong, Jiachen Wan, Lu Si, Yixin Meng, Yanmin Dong, Shaoxiong Liu, Honghui He, Hui Ma	2020	58
19	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis European Journal of Cancer ·Xinan Sheng, Yan Kong, Yiqian Li, Qiannan Zhang, Lu Si, Chuanliang Cui, Zhihong Chi, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, Jie Dai, Jun Guo	2016	53
20	Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients British Journal of Ophthalmology ·Xinan Sheng, Siming Li, Zhihong Chi, Lu Si, Chuanliang Cui, Lili Mao, Bin Lian, Bixia Tang, Xuan Wang, Xieqiao Yan, Yan Kong, Jie Dai, Jun Guo	2015	50

About Lu Si

Lu Si is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Surgery, having authored 309 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (82 papers), Melanoma and MAPK Pathways (61 papers), Cancer Immunotherapy and Biomarkers (57 papers), CAR-T cell therapy research (50 papers), Immunotherapy and Immune Responses (23 papers), Renal cell carcinoma treatment (20 papers), Bladder and Urothelial Cancer Treatments (19 papers) and Optical Polarization and Ellipsometry (12 papers). The work is most often cited by research in Oncology (2.3k citations), Immunology (736 citations), Cancer Research (465 citations), Molecular Biology (1.7k citations) and Ophthalmology (134 citations). Lu Si has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Jun Guo, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Bin Lian, Jie Dai, Bixia Tang and Xieqiao Yan. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, BMC Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Lu Si

Impact in

Papers in i

In The Last Decade

Lu Si

Lu Si's Hit Papers

Peers

Countries citing papers authored by Lu Si

Fields of papers citing papers by Lu Si

All Works

About Lu Si

Explore authors with similar magnitude of impact

Papers in